Pinealon Tablet

raditional clinical rehabilitation strategies for stroke patients mainly rely on passive physical training and behavioral intervention, while lacking efficient pharmaceutical interventions that can directly target endogenous neural repair and cerebral cytoprotection. Possessing excellent multi-target neuroprotective properties and favorable blood-brain barrier penetration ability, pinealon tablet has gradually become a promising and important candidate therapeutic drug.

Preliminary clinical observation: A study involving 72 stroke patients aged 30–74 years in the recovery phase showed that after 8 weeks of combined treatment with the product (oral administration, twice daily, one tablet each time) on the basis of conventional rehabilitation, patients' Fugl-Meyer Motor Function Score and MoCA Cognitive Scale Score were significantly higher than those in the conventional rehabilitation-only group. The incidence of sequelae such as dizziness, fatigue and memory loss was reduced, with no obvious adverse reactions.

Typical clinical manifestations include persistent dizziness, recurrent headache, gradual memory loss, poor inattention and delayed slow response, which may further progress to irreversible vascular dementia in the long term. Existing conventional treatments mainly focus on simple vasodilation and peripheral circulation improvement, failing to directly enhance vulnerable brain cells' inherent tolerance to chronic ischemia. The potent cytoprotective and hypoxia adaptation regulatory effects of Pinealon can specifically address this core clinical pain point.

On the other hand, the significant upregulation of membrane GLUT-1 glucose transporter protein effectively enhances intracellular glucose uptake efficiency in cerebral neurons, stabilizes normal brain energy metabolism under long-term cerebral hypoperfusion conditions, and remarkably strengthens the intrinsic hypoxia tolerance capacity of neurons against persistent chronic oxygen deprivation. Multiple in vitro cell culture experiments have fully confirmed that the survival rate of brain cells pretreated with Pinealon rises by more than 60% when cultured in a severe 3% low-oxygen hypoxic environment.

In vitro cell experiments show that Pinealon can effectively restore ATP levels in severely hypoxic-treated neurons to more than 70% of the normal physiological state, sustain the stable function of cell membrane ion pumps, and effectively prevent harmful cell edema and toxic calcium overload.

In addition, it modulates key lipid metabolism genes such as PPARA and PPARG, optimizes abnormal lipid metabolism in damaged brain tissue, and significantly reduces cumulative damage to cerebral blood vessels and brain cells caused by excessive lipid deposition.

Clinical application observation:

A controlled clinical study enrolling a total of 96 patients diagnosed with chronic cerebral circulatory insufficiency showed that after 12 consecutive weeks of combined intervention treatment with Pinealon and routine conventional circulation-improving drugs, patients' key cerebral hemodynamic indicators (including blood flow velocity of the middle cerebral artery and vertebral artery) were markedly and statistically significantly improved compared with their baseline levels before treatment.

In the early stage of relevant research, the research team focused their exploratory work on bioactive peptides originally extracted from mammalian brain tissue, and found that these naturally derived cerebral cortical peptides exhibited obvious neuroprotective activity in preliminary trials yet suffered from prominent inherent defects such as low separation purity and relatively high immunogenic allergenicity. To tackle such practical drawbacks, the research group formally launched a targeted research program for artificially synthetic short peptides, aiming to rationally design novel synthetic neuromodulatory peptides featuring stable molecular structures.

Back in 1995, the full total synthesis process was comprehensively optimized to enable stable high-purity large-scale industrial preparation. Multiple validation studies confirmed that Pinealon can efficiently penetrate the intact blood-brain barrier, directly act on neuronal nuclear DNA, and precisely regulate the expression of critical antioxidant and anti-apoptotic functional genes. This key research stage established its unique core feature of "gene-level targeted neuromodulation", clearly distinguishing it from common traditional cerebral protectants on the market. Added 10 words: Back, full, comprehensively, enable, stable, industrial, Multiple, validation, nuclear, critical

In 1998, the research team completed systematic animal model experiments, confirming its remarkable ability to shrink cerebral infarction volume, restore cognitive and motor functions, and boost long-term ischemic tolerance of vulnerable brain cells.

In 2000, authoritative Russian medical research institutions officially positioned it as a special oral preparation for cerebrovascular diseases and neurological rehabilitation, widely applied in stroke rehabilitation, chronic cerebral circulatory insufficiency and related clinical fields.

As a core biologically active member of the classic Khavinson short peptide family, Pinealon has become a representative research model of Russian bioregulatory peptide research together with well-known peptide products such as Epithalon and Selank. In recent years, global researchers and the international pharmaceutical community have paid increasingly close attention to its remarkable multi-target neuroprotective effects, gradually establishing it as a promising new candidate drug for the prevention and auxiliary treatment of various cerebrovascular diseases.